A Randomized, Open-label, Multiple-dose, Partial Crossover Study to Explore the Pharmacokinetics and the Pharmacodynamics of YH4808 New Formulation in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 31 May 2017
At a glance
- Drugs YH 4808 (Primary)
- Indications Gastro-oesophageal reflux; NSAID-induced ulcer; Reflux oesophagitis
- Focus Pharmacokinetics
- Sponsors Yuhan
- 17 Feb 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 21 Aug 2014 The study protocol has been amended to exclude YH4808 New Formulation 600mg arm.
- 21 Aug 2014 Planned number of patients changed from 50 to 80 as reported by ClinicalTrials.gov.